[1]ÃÏÙ»Àö,ÂÀÕý.PD-1ÐźÅͨ·ºÍCTLA-4ÔÚÑÛ¿ÆÁìÓòµÄÑо¿½øÕ¹[J].ÑÛ¿ÆнøÕ¹,2021,41(1):001-5.[doi:10.13389/j.cnki.rao.2021.0001]
¡¡MENG Qianli,L Zheng.Advance of PD-1 signaling pathways and CTLA-4 in ophthalmology[J].Recent Advances in Ophthalmology,2021,41(1):001-5.[doi:10.13389/j.cnki.rao.2021.0001]

µã»÷¸´ÖÆ

PD-1ÐźÅͨ·ºÍCTLA-4ÔÚÑÛ¿ÆÁìÓòµÄÑо¿½øÕ¹/HTML

·ÖÏíµ½£º

²Î¿¼ÎÄÏ×/References:

£Û1£Ý¡¡CASTELVECCHI D,GIBNEY E,WARREN M.Laser tricks win physics Nobel£ÛJ£Ý.Nature,2018,562(7725):20.
£Û2£Ý¡¡FREEMAN G J,LONG A J,IWAI Y,BOURQUE K,CHERNOVA T,NISHIMURA H,et al.Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation£ÛJ£Ý.J Exp Med,2000,192(7):1027-1034.
£Û3£Ý¡¡TSENG S,OTSUJI M,GORSKI K,HUANG X,SLANSKY J E,PAI S I,et al.B7-Dc,a new dendritic cell molecule with potent costimulatory properties for T cells£ÛJ£Ý.J Exp Med,2001,193(7):839-846.
£Û4£Ý¡¡RUDD C E,TAYLOR A,SCHNEIDER H.CD28 and CTLA-4 coreceptor expression and signal transduction£ÛJ£Ý.Immunol Rev,2009,229(1):12-26.
£Û5£Ý¡¡COLLINS A V,BRODIE D W,GILBERT R J,IABONI A,MANSO-SANCHO R,WALSE B,et al.The interaction properties of costimulatory molecules revisited£ÛJ£Ý.Immunity,2002,17(2):201-210.
£Û6£Ý¡¡WOLCHOK J D,SAENGER Y.The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation£ÛJ£Ý.Oncologist,2008,13(S4):2-9.
£Û7£Ý¡¡NIEDERKORN J Y.The immune privilege of corneal grafts£ÛJ£Ý.Prog Retin Eye Res,2003,74(2):167-171.
£Û8£Ý¡¡SUGITA S,USUI Y,HORIE S,FUTAGAMI Y,YAMADA Y,MA J,et al.Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1⁺ T helper 1 cells by a contact-dependent mechanism£ÛJ£Ý.Invest Ophthalmol Vis Sci,2009,50(1):263-272.
£Û9£Ý¡¡MENG Q L,YANG P Z,LI B,ZHOU H Y,HUANG X K,ZHU L X,et al.CD4⁺PD-1⁺ T cells acting as regulatory cells during the induction of anterior chamber-associated immune deviation£ÛJ£Ý.Invest Ophthalmol Vis Sci,2006,47(10):4444-4452.
£Û10£Ý¡¡ZHU X,YANG P,ZHOU H,LI B,HUANG X,MENG Q,et al .CD4⁺CD25⁺Tregs express an increased LAG-3 and CTLA-4 in anterior chamber-associated immune deviation£ÛJ£Ý.Graefes Arch Clin Exp Ophthalmol,2007,245(10):1549-1557.
£Û11£Ý¡¡SUGITA S,KEINO H,FUTAGAMI Y,TAKASE H,MOCHIZUKI M,STEIN-STREILEIN J,et al.B7⁺ iris pigment epithelial cells convert T cells into CTLA-4⁺,B7-expressing CD8⁺ regulatory T cells£ÛJ£Ý.Invest Ophthalmol Vis Sci,2006,47(12):5376-5384.
£Û12£Ý¡¡SUGITA S,HORIE S,YAMADA Y,KEINO H,USUI Y,TAKEUCHI M,et al.Suppression of bystander T helper 1 cells by iris pigment epithelium-inducing regulatory T cells via negative costimulatory signals£ÛJ£Ý.Invest Ophthalmol Vis Sci,2010,51(5):2529-2536.
£Û13£Ý¡¡CHARLES E,JOSHI S,ASH J D,FOX B A,FARRIS A D,BZIK D J,et al.CD4 T-cell suppression by cells from toxoplasma gondii-infected retinas is mediated by surface protein PD-L1£ÛJ£Ý.Infect Immun,2010,78(8):3484-3492.
£Û14£Ý¡¡KE Y,SUN D,JIANG G,KAPLAN H J,SHAO H.PD-L1^hi retinal pigment epithelium (RPE) cells elicited by inflammatory cytokines induce regulatory activity in uveitogenic T cells£ÛJ£Ý.J Leukoc Biol,2010,88(6):1241-1249.
£Û15£Ý¡¡SUGITA S,KAWAZOE Y,IMAI A,USUI Y,TAKAHASHI M,MOCHIZUKI M.Suppression of IL-22-producing T helper 22 cells by RPE cells via PD-L1/PD-1 interactions£ÛJ£Ý.Invest Ophthalmol Vis Sci,2013,54(10):6926-6933.
£Û16£Ý¡¡MUHAMMAD F,WANG D,MONTIETH A,LEE S,PREBLE J,FOSTER C S,et al.PD-1⁺ melanocortin receptor dependent-Treg cells prevent autoimmune disease£ÛJ£Ý.Sci Rep,2019,9(1):16941.
£Û17£Ý¡¡MENG Q L,YANG P Z,GUO H K,ZHANG L,CHEN X,JIANG Z X,et al.Characteristic expression of PD-1 and its ligands mRNAs in patients with noninfectious uveitis£ÛJ£Ý.Int J Clin Exp Med,2016,9(1):323-329.
£Û18£Ý¡¡SHIELDS C L,SAY E A T,MASHAYEKHI A,GARG S J,DUNN J P,SHIELDS J A.Assessment of CTLA-4 deficiency-related autoimmune choroidopathy response to abatacept£ÛJ£Ý.JAMA Ophthalmol,2016,134(7):844-846.
£Û19£Ý¡¡HOU S,DU L,LEI B,PANG C P,ZHANG M,ZHUANG W,et al.Genome-wide association analysis of Vogt-Koyanagi-Harada syndrome identifies two new susceptibility loci at 1p31.2 and 10q21.3£ÛJ£Ý.Nat Genet,2014,46(9):1007-1011.
£Û20£Ý¡¡CAO S,CHEE S P,YU H G,SUKAVATCHARIN S,WU L,KIJLSTRA A,et al.Investigation of the association of Vogt-Koyanagi-Harada syndrome with IL23R-C1orf141 in Han Chinese singaporean and ADO-ZNF365-EGR2 in Thai£ÛJ£Ý.Br J Ophthalmol,2016,100(3):436-442.
£Û21£Ý¡¡SHI T,L¦a W,ZHANG L,CHEN J,CHEN H.Association of HLA-DR4/HLA-DRB1^*04 with Vogt-Koyanagi-Harada disease:a systematic review and meta-analysis£ÛJ£Ý.Sci Rep,2014,4(1):1-7.
£Û22£Ý¡¡MENG Q,LIU X,YANG P,HOU S,DU L,ZHOU H,et al.PDCD1 genes may protect against extraocular manifestations in Chinese Han patients with Vogt-Koyanagi-Harada syndrome£ÛJ£Ý.Mol Vis,2009,15:386-392.
£Û23£Ý¡¡GUL A,HAJEER A H,WORTHINGTON J,BARRETT J H,OLLIER W E,SILMAN A J.Evidence for linkage of the HLA-B locus in Behcet¡¯s disease,obtained using the transmission disequilibrium test£ÛJ£Ý.Arthritis Rheum,2001,44(1):239-240.
£Û24£Ý¡¡DU L,YANG P,HOU S,ZHOU H,KIJLSTRA A.No association of CTLA-4 polymorphisms with susceptibility to Behcet disease£ÛJ£Ý.Br J Ophthalmol,2009,93(10):1378-1381.
£Û25£Ý¡¡PFLUGFELDER S C,de PAIVA C S,LI D,STERN M E.Epithelial-immune cell interaction in dry eye£ÛJ£Ý.Cornea,2008,27(Suppl 1):S9-S11.
£Û26£Ý¡¡SHEN L,JIN Y,FREEMAN G J,SHARPE A H,DANA M R.The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival£ÛJ£Ý.J Immunol,2007,179(6):3672-3679.
£Û27£Ý¡¡EL A J,GOYAL S,ZHANG Q,FREEMAN G J,SHARPE A H,DANA R.Regulation of T-cell chemotaxis by programmed death-ligand 1 (PD-L1) in dry eye-associated corneal inflammation£ÛJ£Ý.Invest Ophthalmol Vis Sci,2010,51(7):3418-3423.
£Û28£Ý¡¡JIANG Z,YAN Y,DONG J,DUAN L.PD-1 expression on uveal melanoma induces tumor proliferation and predicts poor patient survival£ÛJ£Ý.Int J Biol Markers,2020:35(3):50-58.
£Û29£Ý¡¡YANG W,CHEN P W,LI H,ALIZADEH H,NIEDERKORN J Y.PD-L1:PD-1 interaction contributes to the functional suppression of T-Cell responses to human uveal melanoma cells in vitro£ÛJ£Ý.Invest Ophthalmol Vis Sci,2008,49(6):2518-2525.
£Û30£Ý¡¡ALGAZI A P,TSAI K K,SHOUSHTARI A N,MUNHOZ R R,EROGLU Z,PIULATS J M,et al.Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies£ÛJ£Ý.Cancer,2016,122(21):3344-3353.
£Û31£Ý¡¡JAVED A,ARGUELLO D,JOHNSTON C,GATALICA Z,TERAI M,WEIGHT R M,et al.PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma£ÛJ£Ý.Immunotherapy,2017,9(16):1323-1330.
£Û32£Ý¡¡JOHNSON D B,BAO R,ANCELL K K,DANIELS A B,WALLACE D,SOSMAN J A,et al.Response to anti-PD-1 in uveal melanoma without high-volume liver metastasis£ÛJ£Ý.J Natl Compr Canc Netw,2019,17(2):114-117.
£Û33£Ý¡¡BENDER C,ENK A,GUTZMER R,HASSEL J C.Anti-PD-1 antibodies in metastatic uveal melanoma:a treatment option?£ÛJ£Ý.Cancer Med,2017,6(7):1581-1586.
£Û34£Ý¡¡AFZAL M Z,MABAERA R,SHIRAI K.Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone£ÛJ£Ý.J Immunother Cancer,2018,6(1):1-8.
£Û35£Ý¡¡HEPPT M V,HEINZERLING L,K¦FHLER K C,FORSCHNER A,KIRCHBERGER M C,LOQUAI C,et al.Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition£ÛJ£Ý.Eur J Cancer,2017,82:56-65.
£Û36£Ý¡¡TSAI K K,ALGAZI A P.Are PD-1 antibodies safe for use in metastatic uveal melanoma?£ÛJ£Ý.Melanoma Manag,2017,4(2):79-82.
£Û37£Ý¡¡CAO J,BROUWER N J,RICHARDS K E,MARINKOVIC M,van DUINEN S,HURKMANS D,et al.PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma£ÛJ£Ý.Oncotarget,2017,8(33):54722-54734.
£Û38£Ý¡¡NAGARAJAN P,EL-HADAD C,GRUSCHKUS S K,NING J,HUDGENS C W,SAGIV O,et al.PD-L1/PD1 expression,composition of tumor-associated immune infiltrate,and HPV status in conjunctival squamous cell carcinoma£ÛJ£Ý.Invest Ophthalmol Vis Sci,2019,60(6):2388-2398.
£Û39£Ý¡¡EJAZ S,CHEKAROVA I,EIAZ A,SOUHAIL A,LIM C W.Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy£ÛJ£Ý.Diabetes Obes Metab,2008,10(1):53-63.
£Û40£Ý¡¡HAMMES H P.Pericytes and the pathogenesis of diabetic retinopathy£ÛJ£Ý.Horm Metab Res,2005,37 Suppl 1:39-43.
£Û41£Ý¡¡TU Z,LI Y,SMITH D S,SHEIBANI N,HUANG S,KERN T,et al.Retinal pericytes inhibit activated T cell proliferation£ÛJ£Ý.Invest Ophthalmol Vis Sci,2011,52(12):9005-9010.
£Û42£Ý¡¡FANG M,MENG Q,GUO H,WANG L,ZHAO Z,ZHANG L,et al.Programmed Death 1 (PD-1) is involved in the development of proliferative diabetic retinopathy by mediating activation-induced apoptosis£ÛJ£Ý.Mol Vis,2015,21:901-910.
£Û43£Ý¡¡PYZIK A,GRYWALSKA E,MATYJASZEK-MATUSZEK B,SMOLE N£§A,PYZIK D,ROLI N£§SKI J.Frequencies of PD-1- positive T CD3+CD4+,T CD3+CD8+ and B CD19+ lymphocytes in female patients with Graves¡¯ disease and healthy controls- preliminary study£ÛJ£Ý.Mol Cell Endocrinol,2017,448:28-33.
£Û44£Ý¡¡NEWBY P R,ROBERTS-DAVIES E L,BRAND O J,HEWARD J M,FRANKLYN J A,GOUGH S C L,et al.Tag SNP screening of the PDCD1 gene for association with Graves? disease£ÛJ£Ý.Clin Endocrinol (Oxf),2007,67(1):125-128.
£Û45£Ý¡¡CHEN D,CHU Y,WEN Y,LIN W,HOUR A,WANG W.Investigation of the correlation between Graves¡¯ Ophthalmopathy and CTLA4 gene polymorphism£ÛJ£Ý.J Clin Med,2019,8(11):1842.
£Û46£Ý¡¡CHONG K K,CHIANG S W,WONG G W,TAM P O,NG T K,HU Y J,et al.Association of CTLA-4 and IL-13 gene polymorphisms with Graves¡¯ disease and ophthalmopathy in Chinese children£ÛJ£Ý.Invest Ophthalmol Vis Sci,2008,49(6):2409-2415.
£Û47£Ý¡¡ANTOUN J,TITAH C,COCHEREAU I.Ocular and orbital side-effects of checkpoint inhibitors£ÛJ£Ý.Curr Opin Oncol,2016,28(4):288-294.
£Û48£Ý¡¡MISEROCCHI E,CIMMINIELLO C,MAZZOLA M,RUSSO V,MODORATI G M.New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient£ÛJ£Ý.Can J Ophthalmol,2015,50(1):e2-e4.
£Û49£Ý¡¡MODJTAHEDI B S,MAIBACH H,PARK S.Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma£ÛJ£Ý.Cutan Ocul Toxicol,2013,32(4):341-343.
£Û50£Ý¡¡ABDEL-WAHAB N,SHAH M,SUAREZ-ALMAZOR M E.Adverse events associated with immune checkpoint blockade in patients with cancer:a systematic review of case reports£ÛJ£Ý.PLoS One,2016,11(7):e160221.
£Û51£Ý¡¡SUN M M,LEVINSON R,FILIPOWICZ A D O,ANESI S,KAPLAN H,WANG W,et al.Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition£ÛJ£Ý.Ocul Immunol Inflamm,2020,28(2):217-227.
£Û52£Ý¡¡DALVIN L A,SHIELDS C L,ORLOFF M,SATO T,SHIELDS J A.Checkpoint inhibitor immune therapy:systemic indications and ophthalmic side effects£ÛJ£Ý.Retina,2018,38(6):1063-1078.
£Û53£Ý¡¡MATSUO T,YAMASAKI O.Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody),interposed by vemurafenib (BRAF inhibitor),for metastatic cutaneous malignant melanoma£ÛJ£Ý.Clin Case Rep,2017,5(5):694-700.
£Û54£Ý¡¡OBATA S,SAISHIN Y,TERAMURA K,OHJI M.Vogt-Koyanagi-Harada disease-like uveitis during nivolumab (anti-PD-1 antibody) treatment for metastatic cutaneous malignant melanoma£ÛJ£Ý.Case Rep Ophthalmol,2019,10(1):67-74.
£Û55£Ý¡¡KROHN J,HANKEN G,HERLOFSEN O.Choroidal naevus regression associated with PD-1 inhibitor monotherapy for metastatic cutaneous malignant melanoma£ÛL£Ý.Acta Ophthalmol,2020,98(2):e262-e264.
£Û56£Ý¡¡MORI S,KURIMOTO T,UEDA K,ENOMOTO H,SAKAMOTO M,KESHI Y,et al.Optic neuritis possibly induced by anti-PD-L1 antibody treatment in a patient with non-small cell lung carcinoma£ÛJ£Ý.Case Rep Ophthalmol,2018,9(2):348-356.
£Û57£Ý¡¡BITTON K,MICHOT J,BARREAU E,LAMBOTTE O,HAIGH O,MARABELLE A,et al.Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy£ÛJ£Ý.Am J Ophthalmol,2019,202:109-117.
£Û58£Ý¡¡DAVIS M E,FRANCIS J H.Cancer therapy with checkpoint inhibitors:establishing a role for ophthalmology£ÛJ£Ý.Semin Oncol Nurs,2017,33(4):415-424.